MoneyWorks4Me

Glenmark Pharmaceuticals informs about press release

19 Oct 2018 Evaluate

Glenmark Pharmaceuticals has informed about press release titled ‘Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference.’

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1752.50
Dr. Reddys Labs. 1180.00
Cipla 1305.00
Lupin 1942.00
Zydus Lifesciences 1115.20
View more..